Synaptic roles of cyclin-dependent kinase 5 & its implications in epilepsy

被引:16
作者
Dixit, Aparna Banerjee [1 ]
Banerjee, Jyotirmoy [1 ]
Tripathi, Manjari [2 ]
Sarkar, Chitra [3 ]
Chandra, P. Sarat [4 ]
机构
[1] All India Inst Med Sci AIIMS Collaborat, NBRC, Ctr Excellence Epilepsy, Gurugram 122051, Haryana, India
[2] AIIMS, Dept Neurol, New Delhi, India
[3] AIIMS, Dept Pathol, New Delhi, India
[4] AIIMS, Dept Neurosurg, New Delhi, India
关键词
Cyclin-dependent kinase 5; epilepsy; epileptogenesis; neurodegenerative diseases; pharmacoresistant; seizures; synaptic plasticity; ACTIVATED PROTEIN-KINASE; CDK5; PHOSPHORYLATES; DNA-DAMAGE; P35; HIPPOCAMPAL; LOCALIZATION; EXPRESSION; AMPHIPHYSIN-1; ORGANIZATION; PLASTICITY;
D O I
10.4103/ijmr.IJMR_1249_14
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
There is an urgent need to understand the molecular mechanisms underlying epilepsy to find novel prognostic/diagnostic biomarkers to prevent epilepsy patients at risk. Cyclin-dependent kinase 5 (CDK5) is involved in multiple neuronal functions and plays a crucial role in maintaining homeostatic synaptic plasticity by regulating intracellular signalling cascades at synapses. CDK5 deregulation is shown to be associated with various neurodegenerative diseases such as Alzheimer's disease. The association between chronic loss of CDK5 and seizures has been reported in animal models of epilepsy. Genetic expression of CDK5 at transcriptome level has been shown to be abnormal in intractable epilepsy. In this review various possible mechanisms by which deregulated CDK5 may alter synaptic transmission and possibly lead to epileptogenesis have been discussed. Further, CDK5 has been proposed as a potential biomarker as well as a pharmacological target for developing treatments for epilepsy.
引用
收藏
页码:178 / 187
页数:10
相关论文
共 97 条
  • [11] Phosphorylation of DARPP-32 by Cdk5 modulates dopamine signalling in neurons
    Bibb, JA
    Snyder, GL
    Nishi, A
    Yan, Z
    Meijer, L
    Fienberg, AA
    Tsai, LH
    Kwon, YT
    Girault, JA
    Czernik, AJ
    Huganir, RL
    Hemmings, HC
    Nairn, AC
    Greengard, P
    [J]. NATURE, 1999, 402 (6762) : 669 - 671
  • [12] Long-term potentiation and long-term depression: a clinical perspective
    Bliss, Timothy V. P.
    Cooke, Sam F.
    [J]. CLINICS, 2011, 66 : 3 - 17
  • [13] The role of dopamine signaling in epileptogenesis
    Bozzi, Yuri
    Borrelli, Emiliana
    [J]. FRONTIERS IN CELLULAR NEUROSCIENCE, 2013, 7
  • [14] α2-chimaerin, cyclin-dependent kinase 5/p35, and its target collapsin response mediator protein-2 are essential components in semaphorin 3A-induced growth-cone collapse
    Brown, M
    Jacobs, T
    Eickholt, B
    Ferrari, G
    Teo, M
    Monfries, C
    Qi, RZ
    Leung, T
    Lim, L
    Hall, C
    [J]. JOURNAL OF NEUROSCIENCE, 2004, 24 (41) : 8994 - 9004
  • [15] Changes in the expression of novel Cdk5 activator messenger RNA (p39(nck5ai) mRNA) during rat brain development
    Cai, XH
    Tomizawa, K
    Tang, DM
    Lu, YF
    Moriwaki, A
    Tokuda, M
    Nagahata, S
    Hatase, O
    Matsui, H
    [J]. NEUROSCIENCE RESEARCH, 1997, 28 (04) : 355 - 360
  • [16] Epilepsy surgery: Recommendations for India
    Chandra, P. Sarat
    Tripathi, Manjari
    [J]. ANNALS OF INDIAN ACADEMY OF NEUROLOGY, 2010, 13 (02) : 87 - 93
  • [17] Chen JS, 2000, J NEUROSCI, V20, P8965
  • [18] Glycogen synthase kinase 3 regulates N-methyl-D-aspartate receptor channel trafficking and function in cortical neurons
    Chen, Paul
    Gu, Zhenglin
    Liu, Wenhua
    Yan, Zhen
    [J]. MOLECULAR PHARMACOLOGY, 2007, 72 (01) : 40 - 51
  • [19] Pctaire1 interacts with p35 and is a novel substrate for Cdk5/p35
    Cheng, K
    Li, Z
    Fu, WY
    Wang, JH
    Fu, AKY
    Ip, NY
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (35) : 31988 - 31993
  • [20] Cyclin-dependent kinase 5 regulates dopaminergic and glutamatergic transmission in the striatum
    Chergui, K
    Svenningsson, P
    Greengard, P
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2004, 101 (07) : 2191 - 2196